Especially, DLBCL with M1-polarization (high CD68/CD163 ratio) described by positive CD68 immunohistochemistry staining presented better treatment response and survival outcomes than M2-polarization (low CD68/CD163 ratio) (13, 14). This evidence concerns the gene CD163 and diffuse large B-cell lymphoma.